Active Biotech AB (ACTI) — Working Capital to Net Assets Ratio
Active Biotech AB (ACTI) has a Working Capital to Net Assets ratio of 46.7% as of September 2025. Working capital of Skr2.10 Million (current assets of Skr14.20 Million minus current liabilities of Skr12.10 Million) is measured against net assets of Skr4.50 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See ACTI equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Active Biotech AB Working Capital to Net Assets (2002–2024)
This chart shows how Active Biotech AB's Working Capital to Net Assets ratio has evolved across 23 annual periods from 2002 to 2024. As of September 2025, the ratio stands at 46.7%, reflecting working capital of Skr2.10 Million against net assets of Skr4.50 Million SEK. Check ACTI goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Active Biotech AB (2002–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Active Biotech AB from 2002 to 2024, covering 23 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see ACTI market cap overview.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 94.5% | Skr30.30 Million | Skr32.07 Million | Skr39.20 Million | Skr8.90 Million | ▲ +2.1 pp |
| 2023 | 92.4% | Skr28.33 Million | Skr30.67 Million | Skr38.71 Million | Skr10.38 Million | ▼ -0.5 pp |
| 2022 | 92.9% | Skr32.06 Million | Skr34.51 Million | Skr44.12 Million | Skr12.06 Million | ▼ -5.6 pp |
| 2021 | 98.5% | Skr45.95 Million | Skr46.67 Million | Skr55.86 Million | Skr9.90 Million | ▲ +3.8 pp |
| 2020 | 94.7% | Skr20.93 Million | Skr22.11 Million | Skr30.28 Million | Skr9.35 Million | ▼ -3.1 pp |
| 2019 | 97.8% | Skr52.59 Million | Skr53.78 Million | Skr63.76 Million | Skr11.17 Million | ▼ -0.9 pp |
| 2018 | 98.7% | Skr86.75 Million | Skr87.92 Million | Skr301.16 Million | Skr214.41 Million | ▲ +0.5 pp |
| 2017 | 98.2% | Skr76.26 Million | Skr77.68 Million | Skr302.10 Million | Skr225.84 Million | ▲ +64.5 pp |
| 2016 | 33.7% | Skr61.44 Million | Skr182.56 Million | Skr84.80 Million | Skr23.36 Million | ▼ -3.5 pp |
| 2015 | 37.1% | Skr67.07 Million | Skr180.60 Million | Skr119.64 Million | Skr52.56 Million | ▼ -23.6 pp |
| 2014 | 60.8% | Skr246.31 Million | Skr405.31 Million | Skr340.88 Million | Skr94.58 Million | ▼ -0.5 pp |
| 2013 | 61.3% | Skr248.42 Million | Skr405.41 Million | Skr386.77 Million | Skr138.35 Million | ▲ +6.3 pp |
| 2012 | 55.0% | Skr186.90 Million | Skr339.92 Million | Skr315.24 Million | Skr128.34 Million | ▼ -15.6 pp |
| 2011 | 70.5% | Skr354.12 Million | Skr501.99 Million | Skr475.85 Million | Skr121.73 Million | ▲ +34.8 pp |
| 2010 | 35.7% | Skr64.91 Million | Skr181.76 Million | Skr144.58 Million | Skr79.67 Million | ▼ -26.6 pp |
| 2009 | 62.3% | Skr117.60 Million | Skr188.64 Million | Skr179.50 Million | Skr61.90 Million | ▲ +6.9 pp |
| 2008 | 55.5% | Skr90.78 Million | Skr163.61 Million | Skr148.40 Million | Skr57.61 Million | ▼ -1.5 pp |
| 2007 | 57.0% | Skr108.05 Million | Skr189.57 Million | Skr157.39 Million | Skr49.34 Million | ▲ +115.5 pp |
| 2006 | -58.5% | Skr-35.32 Million | Skr60.36 Million | Skr111.87 Million | Skr147.19 Million | ▼ -144.3 pp |
| 2005 | 85.8% | Skr151.75 Million | Skr176.81 Million | Skr188.07 Million | Skr36.31 Million | ▼ -24.0 pp |
| 2004 | 109.8% | Skr178.27 Million | Skr162.30 Million | Skr230.38 Million | Skr52.12 Million | ▲ +41.1 pp |
| 2003 | 68.8% | Skr199.13 Million | Skr289.58 Million | Skr250.02 Million | Skr50.89 Million | ▼ -3.5 pp |
| 2002 | 72.3% | Skr274.83 Million | Skr380.27 Million | Skr359.39 Million | Skr84.56 Million | — |